Emergent BioSolutions (EBS) Current Deferred Revenue (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Current Deferred Revenue of $17.6 million for Q1 2026, up 252.0% quarter-over-quarter from $5.0 million in Q4 2025.
Emergent BioSolutions (EBS) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.6 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $17.6 million (changed N/A YoY), while the FY2025 annual figure was $5.0 million, changed N/A from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $17.6 million, up from $5.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $17.6 million in Q1 2026, with the low at $5.0 million in Q4 2025.
- The 3-year median for Current Deferred Revenue is $15.9 million (2022), against an average of $12.8 million.
- Peak annual rise in Current Deferred Revenue reached 85.9% in 2022, while the deepest fall reached 85.9% in 2022.
- Emergent BioSolutions' Current Deferred Revenue stood at $15.9 million in 2022, then sank by 68.55% to $5.0 million in 2025, then soared by 252.0% to $17.6 million in 2026.
- Business Quant data shows EBS's Current Deferred Revenue at $17.6 million in Q1 2026, $5.0 million in Q4 2025, and $15.9 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.90 Mn |
| Mar 31, 2026 | 17.60 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Mar 31, 2022 | 15.90 Mn |
| Dec 31, 2021 | 16.40 Mn |
| Sep 30, 2021 | 82.10 Mn |
| Jun 30, 2021 | 103.40 Mn |
| Mar 31, 2021 | 112.80 Mn |
| Dec 31, 2020 | 100.10 Mn |
| Sep 30, 2020 | 79.90 Mn |
| Jun 30, 2020 | 32.70 Mn |
| Mar 31, 2020 | 89.40 Mn |
| Dec 31, 2019 | 88.90 Mn |
| Sep 30, 2019 | 89.60 Mn |
| Jun 30, 2019 | 89.50 Mn |
| Mar 31, 2019 | 75.20 Mn |
| Dec 31, 2018 | 73.10 Mn |
| Sep 30, 2018 | 76.13 Mn |
| Jun 30, 2018 | 9.75 Mn |
| Mar 31, 2018 | 66.33 Mn |